Therapeutic Drug Monitoring of Ganciclovir: Where Are We?
Ganciclovir is the mainstay of therapy for the prophylaxis and treatment of Cytomegalovirus. However, therapy with this antiviral agent is hindered by side effects such as myelosuppression, which often leads to therapy cessation. Underdosing, as an attempt to prevent side effects, can lead to drug r...
Uložené v:
| Vydané v: | Therapeutic drug monitoring Ročník 44; číslo 1; s. 138 |
|---|---|
| Hlavní autori: | , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
United States
01.02.2022
|
| Predmet: | |
| ISSN: | 1536-3694, 1536-3694 |
| On-line prístup: | Zistit podrobnosti o prístupe |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Ganciclovir is the mainstay of therapy for the prophylaxis and treatment of Cytomegalovirus. However, therapy with this antiviral agent is hindered by side effects such as myelosuppression, which often leads to therapy cessation. Underdosing, as an attempt to prevent side effects, can lead to drug resistance and therapy failure. Therapeutic drug monitoring (TDM) has been used to overcome these problems. The purpose of this narrative review was to give an overview of ganciclovir TDM, available assays, population pharmacokinetic models, and discuss the current knowledge gaps.
For this narrative review, a nonsystematic literature search was performed on the PubMed database in April 2021. The following search terms were used: ganciclovir, valganciclovir, pharmacokinetics, pharmacodynamics, population pharmacokinetics, therapeutic drug monitoring, bioassay, liquid chromatography coupled with tandem mass spectrometry, liquid chromatography, chromatography, spectrophotometry, and toxicity. In addition, the reference lists of the included articles were screened.
The most common bioanalysis method identified was liquid chromatography coupled with tandem mass spectrometry. There are different models presenting ganciclovir IC50; however, establishing a pharmacokinetic/pharmacodynamic target for ganciclovir based on preclinical data is difficult because there are no studies combining dynamic drug exposure in relation to inhibition of viral replication. The data on ganciclovir TDM show large interindividual variability, indicating that TDM may play a role in modifying the dose to reduce toxicity and prevent treatment failure related to low concentrations. The main hurdle for implementing TDM is the lack of robust data to define a therapeutic window.
Although the pharmacokinetics (PK) involved is relatively well-described, both the pharmacodynamics (PD) and pharmacokinetic/pharmacodynamic relationship are not. This is because the studies conducted to date have mainly focused on estimating ganciclovir exposure, and owing to the limited therapeutic options for CMV infections, future studies on ganciclovir are warranted. |
|---|---|
| AbstractList | Ganciclovir is the mainstay of therapy for the prophylaxis and treatment of Cytomegalovirus. However, therapy with this antiviral agent is hindered by side effects such as myelosuppression, which often leads to therapy cessation. Underdosing, as an attempt to prevent side effects, can lead to drug resistance and therapy failure. Therapeutic drug monitoring (TDM) has been used to overcome these problems. The purpose of this narrative review was to give an overview of ganciclovir TDM, available assays, population pharmacokinetic models, and discuss the current knowledge gaps.
For this narrative review, a nonsystematic literature search was performed on the PubMed database in April 2021. The following search terms were used: ganciclovir, valganciclovir, pharmacokinetics, pharmacodynamics, population pharmacokinetics, therapeutic drug monitoring, bioassay, liquid chromatography coupled with tandem mass spectrometry, liquid chromatography, chromatography, spectrophotometry, and toxicity. In addition, the reference lists of the included articles were screened.
The most common bioanalysis method identified was liquid chromatography coupled with tandem mass spectrometry. There are different models presenting ganciclovir IC50; however, establishing a pharmacokinetic/pharmacodynamic target for ganciclovir based on preclinical data is difficult because there are no studies combining dynamic drug exposure in relation to inhibition of viral replication. The data on ganciclovir TDM show large interindividual variability, indicating that TDM may play a role in modifying the dose to reduce toxicity and prevent treatment failure related to low concentrations. The main hurdle for implementing TDM is the lack of robust data to define a therapeutic window.
Although the pharmacokinetics (PK) involved is relatively well-described, both the pharmacodynamics (PD) and pharmacokinetic/pharmacodynamic relationship are not. This is because the studies conducted to date have mainly focused on estimating ganciclovir exposure, and owing to the limited therapeutic options for CMV infections, future studies on ganciclovir are warranted. Ganciclovir is the mainstay of therapy for the prophylaxis and treatment of Cytomegalovirus. However, therapy with this antiviral agent is hindered by side effects such as myelosuppression, which often leads to therapy cessation. Underdosing, as an attempt to prevent side effects, can lead to drug resistance and therapy failure. Therapeutic drug monitoring (TDM) has been used to overcome these problems. The purpose of this narrative review was to give an overview of ganciclovir TDM, available assays, population pharmacokinetic models, and discuss the current knowledge gaps.BACKGROUNDGanciclovir is the mainstay of therapy for the prophylaxis and treatment of Cytomegalovirus. However, therapy with this antiviral agent is hindered by side effects such as myelosuppression, which often leads to therapy cessation. Underdosing, as an attempt to prevent side effects, can lead to drug resistance and therapy failure. Therapeutic drug monitoring (TDM) has been used to overcome these problems. The purpose of this narrative review was to give an overview of ganciclovir TDM, available assays, population pharmacokinetic models, and discuss the current knowledge gaps.For this narrative review, a nonsystematic literature search was performed on the PubMed database in April 2021. The following search terms were used: ganciclovir, valganciclovir, pharmacokinetics, pharmacodynamics, population pharmacokinetics, therapeutic drug monitoring, bioassay, liquid chromatography coupled with tandem mass spectrometry, liquid chromatography, chromatography, spectrophotometry, and toxicity. In addition, the reference lists of the included articles were screened.METHODSFor this narrative review, a nonsystematic literature search was performed on the PubMed database in April 2021. The following search terms were used: ganciclovir, valganciclovir, pharmacokinetics, pharmacodynamics, population pharmacokinetics, therapeutic drug monitoring, bioassay, liquid chromatography coupled with tandem mass spectrometry, liquid chromatography, chromatography, spectrophotometry, and toxicity. In addition, the reference lists of the included articles were screened.The most common bioanalysis method identified was liquid chromatography coupled with tandem mass spectrometry. There are different models presenting ganciclovir IC50; however, establishing a pharmacokinetic/pharmacodynamic target for ganciclovir based on preclinical data is difficult because there are no studies combining dynamic drug exposure in relation to inhibition of viral replication. The data on ganciclovir TDM show large interindividual variability, indicating that TDM may play a role in modifying the dose to reduce toxicity and prevent treatment failure related to low concentrations. The main hurdle for implementing TDM is the lack of robust data to define a therapeutic window.RESULTSThe most common bioanalysis method identified was liquid chromatography coupled with tandem mass spectrometry. There are different models presenting ganciclovir IC50; however, establishing a pharmacokinetic/pharmacodynamic target for ganciclovir based on preclinical data is difficult because there are no studies combining dynamic drug exposure in relation to inhibition of viral replication. The data on ganciclovir TDM show large interindividual variability, indicating that TDM may play a role in modifying the dose to reduce toxicity and prevent treatment failure related to low concentrations. The main hurdle for implementing TDM is the lack of robust data to define a therapeutic window.Although the pharmacokinetics (PK) involved is relatively well-described, both the pharmacodynamics (PD) and pharmacokinetic/pharmacodynamic relationship are not. This is because the studies conducted to date have mainly focused on estimating ganciclovir exposure, and owing to the limited therapeutic options for CMV infections, future studies on ganciclovir are warranted.CONCLUSIONSAlthough the pharmacokinetics (PK) involved is relatively well-described, both the pharmacodynamics (PD) and pharmacokinetic/pharmacodynamic relationship are not. This is because the studies conducted to date have mainly focused on estimating ganciclovir exposure, and owing to the limited therapeutic options for CMV infections, future studies on ganciclovir are warranted. |
| Author | Knoester, Marjolein Alffenaar, Jan-Willem C Märtson, Anne-Grete Kim, Hannah Yejin Edwina, Angela E Touw, Daan J Sturkenboom, Marieke G G |
| Author_xml | – sequence: 1 givenname: Anne-Grete orcidid: 0000-0001-6478-1959 surname: Märtson fullname: Märtson, Anne-Grete organization: Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands – sequence: 2 givenname: Angela E surname: Edwina fullname: Edwina, Angela E organization: Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands – sequence: 3 givenname: Hannah Yejin surname: Kim fullname: Kim, Hannah Yejin organization: Marie Bashir Institute of Infectious Diseases and Biosecurity, The University of Sydney, Camperdown, NSW, Australia – sequence: 4 givenname: Marjolein surname: Knoester fullname: Knoester, Marjolein organization: Department of Medical Microbiology and Infection Prevention, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands ; and – sequence: 5 givenname: Daan J surname: Touw fullname: Touw, Daan J organization: Department of Pharmaceutical Analysis, Groningen Research Institute of Pharmacy, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands – sequence: 6 givenname: Marieke G G surname: Sturkenboom fullname: Sturkenboom, Marieke G G organization: Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands – sequence: 7 givenname: Jan-Willem C surname: Alffenaar fullname: Alffenaar, Jan-Willem C organization: Marie Bashir Institute of Infectious Diseases and Biosecurity, The University of Sydney, Camperdown, NSW, Australia |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34610621$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNj0tLw0AUhQep2If-A5Es3aTOezJupLS2ChU3kS7D5GZSR5JMnSQF_70BK_TAuecsPi6cKRo1vrEI3RI8J1irh3W6muNzaSou0IQIJmMmNR-d9TGatu0XxoQnGF-hMeOSYEnJBOn00wZzsH3nIFqFfh-9-cZ1PrhmH_ky2pgGHFT-6MJjtBtYGy0G7-zTNbosTdXam1PO0Mf6OV2-xNv3zetysY1BcMVjhbUQmgBVwBgryXCEKcqiBEpyoDonqgRgUkgtbS4TRo3ME8Uph8JqUHSG7v_-HoL_7m3bZbVrwVaVaazv24wKpSWVIqEDendC-7y2RXYIrjbhJ_ufS38BuO5XaA |
| CitedBy_id | crossref_primary_10_3390_microorganisms11010032 crossref_primary_10_3390_ph16121741 crossref_primary_10_1016_j_beha_2024_101565 crossref_primary_10_1016_j_jiac_2025_102686 crossref_primary_10_3390_ijms25168760 crossref_primary_10_1097_FTD_0000000000001321 crossref_primary_10_3390_pharmaceutics15030941 crossref_primary_10_3390_ijms25052685 crossref_primary_10_1128_aac_01665_22 crossref_primary_10_3390_pharmaceutics15010163 crossref_primary_10_1016_j_farma_2024_09_001 crossref_primary_10_1097_TP_0000000000005374 crossref_primary_10_1007_s40262_025_01526_z crossref_primary_10_1016_j_ijantimicag_2025_107537 crossref_primary_10_1080_1120009X_2024_2395776 crossref_primary_10_1111_tid_14094 crossref_primary_10_1186_s12879_024_10191_9 crossref_primary_10_1124_dmd_122_000856 crossref_primary_10_1097_FPC_0000000000000474 crossref_primary_10_1016_j_idc_2023_06_002 crossref_primary_10_14309_crj_0000000000001536 crossref_primary_10_1080_14740338_2024_2374919 crossref_primary_10_1111_tid_70108 crossref_primary_10_1002_bmc_5315 crossref_primary_10_3389_fpubh_2023_1117412 crossref_primary_10_1007_s40263_024_01082_3 crossref_primary_10_1097_MD_0000000000034946 crossref_primary_10_1002_adhm_202500692 crossref_primary_10_3390_pharmaceutics16050677 crossref_primary_10_1097_TP_0000000000004855 crossref_primary_10_1149_1945_7111_ad2cbd crossref_primary_10_1128_aac_00860_24 crossref_primary_10_1177_10600280241283966 crossref_primary_10_1128_aac_01815_24 crossref_primary_10_1016_j_farma_2024_11_008 crossref_primary_10_1007_s40272_024_00663_5 crossref_primary_10_1097_FTD_0000000000001050 crossref_primary_10_1111_tid_14141 crossref_primary_10_1080_17512433_2022_2093716 crossref_primary_10_1016_j_ejps_2025_107200 crossref_primary_10_1097_INF_0000000000004605 crossref_primary_10_1111_tid_14107 |
| ContentType | Journal Article |
| Copyright | Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. |
| Copyright_xml | – notice: Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1097/FTD.0000000000000925 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1536-3694 |
| ExternalDocumentID | 34610621 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Review |
| GroupedDBID | --- .-D .Z2 0R~ 123 4Q1 4Q2 4Q3 53G 5RE 5VS 71W 8L- AAAAV AAHPQ AAIQE AAMTA AARTV AASCR AAYEP ABASU ABBUW ABDIG ABJNI ABOCM ABVCZ ABXVJ ABZAD ACDDN ACEWG ACGFO ACGFS ACILI ACWDW ACWRI ACXJB ACXNZ ADGGA ADHPY AE6 AENEX AFDTB AHMBA AHQNM AHVBC AINUH AJCLO AJIOK AJNWD AJZMW AKCTQ ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AWKKM BQLVK C45 CGR CS3 CUY CVF DIWNM DU5 E.X EBS ECM EEVPB EIF EX3 F2K F2L F5P FCALG FL- GNXGY GQDEL H0~ HLJTE HZ~ IKREB IN~ IPNFZ JK3 JK8 K8S KD2 KMI L-C N9A NPM O9- OAG OAH ODA OL1 OLG OLV OLW OLZ OPC OPUJH OVD OVDNE OWV OWW OWY OWZ OXXIT P2P PQQKQ RIG RLZ S4R S4S TEORI TSPGW V2I VVN W3M WOQ WOW X3V X3W XYM YFH YOC ZFV ZY1 7X8 ABPXF ABZZY ADKSD AFBFQ AOQMC |
| ID | FETCH-LOGICAL-c5474-7095591c27c333f13335adfdfc21bc29b17fcc365696eb6832a6b87424cde9c72 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 47 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=00007691-202202000-00014&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1536-3694 |
| IngestDate | Mon Sep 08 02:59:49 EDT 2025 Wed Feb 19 02:23:11 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5474-7095591c27c333f13335adfdfc21bc29b17fcc365696eb6832a6b87424cde9c72 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0001-6478-1959 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC8746890 |
| PMID | 34610621 |
| PQID | 2579626582 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2579626582 pubmed_primary_34610621 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-February-01 |
| PublicationDateYYYYMMDD | 2022-02-01 |
| PublicationDate_xml | – month: 02 year: 2022 text: 2022-February-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Therapeutic drug monitoring |
| PublicationTitleAlternate | Ther Drug Monit |
| PublicationYear | 2022 |
| SSID | ssj0014800 |
| Score | 2.5186625 |
| SecondaryResourceType | review_article |
| Snippet | Ganciclovir is the mainstay of therapy for the prophylaxis and treatment of Cytomegalovirus. However, therapy with this antiviral agent is hindered by side... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 138 |
| SubjectTerms | Antiviral Agents - adverse effects Cytomegalovirus Infections - drug therapy Drug Monitoring - methods Ganciclovir - therapeutic use Humans Valganciclovir - pharmacokinetics Valganciclovir - therapeutic use |
| Title | Therapeutic Drug Monitoring of Ganciclovir: Where Are We? |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/34610621 https://www.proquest.com/docview/2579626582 |
| Volume | 44 |
| WOSCitedRecordID | wos00007691-202202000-00014&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV07T8MwELaAMrDwfpSXjIQ6NWpjJ3bMUiFKYaHKUES3qHZsVAklJaGV-u8556GwICHhIUsSJTrfne_5HUK3fWYksC13DHE9xwOT3wmIAq81hhXIwgYuhk3w8TiYTkVYBdzyqqyy1omFoo5TZWPkPWKbJgmcl2Sw-HTs1CibXa1GaGyiFgVTxnI1nzZZBC8oWlBAqJlDmfDq1jnBe6PJsIQurJcg_u9GZnHYjPb--5v7aLcyM_F9yRcHaEMnh6gTljjV6y6eNG1XeRd3cNggWK-PkPhxGw-z5TsuRd_GAHFq8JMF6VAf6Wqe3WFQ55mGL2n8pgfH6HX0OHl4dqoZC47yPVuKWUDQuYpwRSk14LFSfxab2CjiSkUE7JZRioLVJ5iWDOR_xmQA_rSnYi0UJydoK0kTfYZwoLgw0neV1LZRHR6LKTfScKmZ9vqqjW5qkkXAwzYxMUt0usyjhmhtdFrSPVqUYBsRtYDwjLjnf3j7Au0Q251QFFVfopYBCdZXaFutvuZ5dl0wB1zH4cs3BXHBkA |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Therapeutic+Drug+Monitoring+of+Ganciclovir%3A+Where+Are+We%3F&rft.jtitle=Therapeutic+drug+monitoring&rft.au=M%C3%A4rtson%2C+Anne-Grete&rft.au=Edwina%2C+Angela+E&rft.au=Kim%2C+Hannah+Yejin&rft.au=Knoester%2C+Marjolein&rft.date=2022-02-01&rft.eissn=1536-3694&rft.volume=44&rft.issue=1&rft.spage=138&rft_id=info:doi/10.1097%2FFTD.0000000000000925&rft_id=info%3Apmid%2F34610621&rft_id=info%3Apmid%2F34610621&rft.externalDocID=34610621 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1536-3694&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1536-3694&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1536-3694&client=summon |